Merck says new study supports Janumet\'s use to treat type 2 diabetes Sharewatch
Initial treatment with sitagliptin phosphate 50 mg twice daily in combination with metformin 1,000 mg twice daily provided substantial reductions in two types of blood sugar levels, the company said, citing data presented at the 19th World Diabetes Congress in Cape Town. \"Typically, oral medications for type 2 diabetes principally either reduce post-meal glucose levels or reduce fasting blood
New Data Shows Rimonabant Benefited Patients With Type 2 Diabetes By Improving Blood Sugar Control And Reducing Weight Medical News Today
Sanofi-aventis announced today that new data on rimonabant, its first-in-class cannabinoid type 1 (CB1) receptor blocker, showed that patients with type 2 diabetes not currently treated with anti-diabetic medications experienced significant improvements in blood sugar control and weight as we [click link for full article]
New Type 2 Diabetes Drug Delays Disease Progression MedicineNet.com
Title: New Type 2 Diabetes Drug Delays Disease Progression Category: Health News Created: 12/5/2006 2:06:00 AM Last Editorial Review: 12/5/2006 2:05:30 AM
Avandia is more effective than metformin in long-term blood sugar control in type 2 diabetes: Study PharmaBiz
ADOPT has (A Diabetes Outcome Progression Trial) demonstrated that initial treatment with Avandia (rosiglitazone maleate) reduced the risk of monotherapy failure in people with type 2 diabetes by 32 per cent compared to metformin and 63 per cent compared to glyburide at five years.
AFX UK Focus 2006-12-04 14:45 GMT: GlaxoSmithKline's Avandia slows progression of type 2 diabetes - study Interactive Investor
LONDON (AFX) - GlaxoSmithKline PLC's Avandia was found to be better at maintaining the blood sugar levels of people with type 2 diabetes than two other widely-used, older drugs in a large scale study carried out over five years.
New Type 2 Diabetes Drug Delays Disease Progression HealthDay via Yahoo! News
MONDAY, Dec. 4 (HealthDay News) -- One of a new class of diabetes drugs delayed the progression of type 2 diabetes along with the need to add additional medications.
Treating Type 2 Diabetes KABC-TV Los Angeles
A drug that's been around for two centuries may bring scientists closer to controlling diabetes.
New Data Shows AcompliaR Rimonabant Benefited Patients With Type 2 Diabetes by Improving Blood Sugar Control, FinanzNachrichten
Sanofi-aventis announced today that new data on rimonabant, its first-in-class cannabinoid type 1 (CB1) receptor blocker, showed that patients with type 2 diabetes not currently treated with anti-diabetic medications experienced significant improvements in blood sugar control and weight as well as other risk factors such as HDL-cholesterol (good cholesterol) and triglycerides when compared to
AFX UK Focus 2006-12-05 13:59 GMT: Merck says new study supports Janumet's use to treat type 2 diabetes Interactive Investor
LONDON (AFX) - Merck & Co Inc said new data supported the use of its combination therapy Janumet to treat type 2 diabetes in patients.
New Data Shows Acompliar Rimonabant Benefited Patients With Type 2 Diabetes by Improving Blood Sugar Control, CNW Group via Yahoo! Finance
Sanofi-aventis announced today that new data on rimonabant, its first-in-class cannabinoid type 1 receptor blocker, showed that patients with type 2 diabetes not currently treated with anti-diabetic medications experienced significant improvements in blood sugar control and weight as well as other risk factors such as HDL-cholesterol and triglycerides when compared to placebo.
diabetes+two+type: diabetes+two+type